376 related articles for article (PubMed ID: 15547183)
1. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S
Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
4. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
Yeo M; Kim DK; Kim YB; Oh TY; Lee JE; Cho SW; Kim HC; Hahm KB
Clin Cancer Res; 2004 Dec; 10(24):8687-96. PubMed ID: 15623654
[TBL] [Abstract][Full Text] [Related]
5. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
[TBL] [Abstract][Full Text] [Related]
6. Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A; Fais S
Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
[TBL] [Abstract][Full Text] [Related]
7. Manipulating tumor acidification as a cancer treatment strategy.
McCarty MF; Whitaker J
Altern Med Rev; 2010 Sep; 15(3):264-72. PubMed ID: 21155627
[TBL] [Abstract][Full Text] [Related]
8. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
9. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
10. The proton-pump inhibitors: similarities and differences.
Horn J
Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
[TBL] [Abstract][Full Text] [Related]
11. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
[TBL] [Abstract][Full Text] [Related]
12. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors: an update.
Vanderhoff BT; Tahboub RM
Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
[TBL] [Abstract][Full Text] [Related]
14. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors: new drugs and indications.
Mears JM; Kaplan B
Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
[TBL] [Abstract][Full Text] [Related]
16. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R
J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076
[TBL] [Abstract][Full Text] [Related]
18. Effect of proton pump inhibitors on the continuous real time (13)C-urea breath test.
Shirin H; Frenkel D; Shevah O; Levine A; Bruck R; Moss SF; Niv Y; Avni Y
Am J Gastroenterol; 2003 Jan; 98(1):46-50. PubMed ID: 12526935
[TBL] [Abstract][Full Text] [Related]
19. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
20. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]